NASDAQ:IRWD Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis $1.80 +0.03 (+1.41%) As of 12:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Ironwood Pharmaceuticals Stock (NASDAQ:IRWD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IRWD alerts:Sign Up Key Stats Today's Range$1.68▼$1.8550-Day Range$1.70▼$4.6152-Week Range$1.59▼$15.70Volume1.65 million shsAverage Volume3.79 million shsMarket Capitalization$287.25 millionP/E RatioN/ADividend YieldN/APrice Target$10.67Consensus RatingModerate Buy Company OverviewIronwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Read More… Ironwood Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks81st Percentile Overall ScoreIRWD MarketRank™: Ironwood Pharmaceuticals scored higher than 81% of companies evaluated by MarketBeat, and ranked 196th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingIronwood Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageIronwood Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Ironwood Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth110.00% Earnings GrowthEarnings for Ironwood Pharmaceuticals are expected to grow by 110.00% in the coming year, from $0.10 to $0.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ironwood Pharmaceuticals is -59.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ironwood Pharmaceuticals is -59.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ironwood Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.08% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently increased by 2.49%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIronwood Pharmaceuticals does not currently pay a dividend.Dividend GrowthIronwood Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.4 / 5Environmental Score-2.94 Percentage of Shares Shorted6.08% of the float of Ironwood Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIronwood Pharmaceuticals has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Ironwood Pharmaceuticals has recently increased by 2.49%, indicating that investor sentiment is decreasing. News and Social Media2.1 / 5News Sentiment-0.14 News SentimentIronwood Pharmaceuticals has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Ironwood Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest5 people have searched for IRWD on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows2 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ironwood Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $66,753.00 in company stock.Percentage Held by Insiders12.90% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Ironwood Pharmaceuticals' insider trading history. Receive IRWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ironwood Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IRWD Stock News HeadlinesMillrose Properties Set to Join S&P SmallCap 600February 5, 2025 | prnewswire.comSTATE STREET CORP Reduces Stake in Ironwood Pharmaceuticals IncFebruary 5, 2025 | gurufocus.comAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what he might do next. And one widely followed Boston based think tank is stepping forward with their official playbook.February 11, 2025 | Altimetry (Ad)Equities Analysts Offer Predictions for IRWD Q1 EarningsFebruary 3, 2025 | americanbankingnews.comWhat is Leerink Partnrs' Forecast for IRWD Q4 Earnings?February 2, 2025 | americanbankingnews.comIronwood Pharmaceuticals Announces Workforce Reduction and Executive AppointmentFebruary 1, 2025 | americanbankingnews.comIronwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the FutureJanuary 31, 2025 | businesswire.comIronwood Pharma: Strategic Growth Amidst Challenges, Driven by Apra’s PotentialJanuary 31, 2025 | markets.businessinsider.comSee More Headlines IRWD Stock Analysis - Frequently Asked Questions How have IRWD shares performed this year? Ironwood Pharmaceuticals' stock was trading at $4.43 at the beginning of the year. Since then, IRWD stock has decreased by 59.5% and is now trading at $1.7950. View the best growth stocks for 2025 here. How were Ironwood Pharmaceuticals' earnings last quarter? Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by $0.07. The business's revenue for the quarter was down 19.4% on a year-over-year basis. Who are Ironwood Pharmaceuticals' major shareholders? Top institutional shareholders of Ironwood Pharmaceuticals include Pacer Advisors Inc. (7.33%), Charles Schwab Investment Management Inc. (1.24%), Jupiter Asset Management Ltd. (0.76%) and Bank of New York Mellon Corp (0.61%). Insiders that own company stock include Thomas A Mccourt, Mark G Currie, Jason Rickard, Michael Shetzline, Sravan Kumar Emany, Andrew Davis, Minardo John, Julie Mchugh, Jon R Duane, Ronald Silver, Catherine Moukheibir and Marla L Kessler. View institutional ownership trends. How do I buy shares of Ironwood Pharmaceuticals? Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ironwood Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ironwood Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings11/07/2024Today2/11/2025Next Earnings (Estimated)2/20/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:IRWD CUSIP46333X10 CIK1446847 Webwww.ironwoodpharma.com Phone(617) 621-7722Fax617-494-0480Employees220Year FoundedN/APrice Target and Rating Average Stock Price Target$10.67 High Stock Price Target$21.00 Low Stock Price Target$4.00 Potential Upside/Downside+502.6%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,002,240,000.00 Net Margins-0.65% Pretax Margin18.91% Return on Equity-0.96% Return on Assets0.74% Debt Debt-to-Equity RatioN/A Current Ratio3.62 Quick Ratio3.62 Sales & Book Value Annual Sales$442.73 million Price / Sales0.64 Cash FlowN/A Price / Cash FlowN/A Book Value($2.21) per share Price / Book-0.80Miscellaneous Outstanding Shares160,030,000Free Float139,384,000Market Cap$283.25 million OptionableOptionable Beta0.29 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free Report This page (NASDAQ:IRWD) was last updated on 2/11/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredTrump’s “Shock and Awe” Executive OrderPresident Trump has already launched a "shock and awe" flurry of new Executive Orders... He's withdrawn fro...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.